[Clinical analysis of 31 patients with sinonasal neuroendocrine carcinoma]

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jan;36(1):32-35. doi: 10.13201/j.issn.2096-7993.2022.01.007.
[Article in Chinese]

Abstract
in English, Chinese

Objective:To investigate the characteristics and prognostic factors of sinonasal neuroendocrine carcinoma （SNEC）. Methods:The clinical data of 31 patients with SNEC were retrospectively analyzed. Among the 31 patients, 3 cases were simply surgically removed, 4 cases were surgery + radiotherapy, 4 cases were surgery + chemotherapy, 10 cases were surgery + chemoradiotherapy, and 10 cases were simply given chemoradiotherapy without surgery. The study follow-up 8-64 months. Results:By the end of follow-up, 2 patients were lost to follow-up, 17 died, 12 survival, 8 relapsed and 5-year survival rate was 36.4％. High TNM stage, lymph node metastasis, skull base infiltration and Ki-67≥55％ were the negative prognostic factors for survival. Conclusion:SNEC is a rare aggressive tumor, with poor prognosis, high local recurrence rate, metastasis tendency, hidden disease. The comprehensive treatment of surgery combined with chemoradiotherapy is still the best treatment.

目的：探讨鼻腔鼻窦神经内分泌癌（SNEC）的临床特点及影响预后的因素。 方法：回顾性分析31例确诊为SNEC患者的临床资料。31例患者中，单纯手术切除3例，手术+放疗4例，手术+化疗4例，手术+放化疗10例，未行手术单纯放化疗10例。随访8～64个月。 结果：至随访结束，2例患者失访，17例死亡，12例存活，8例复发，5年总生存率36.4％，高TNM分期、淋巴结转移、颅底浸润以及Ki-67≥55％是其预后不良因素。 结论：SNEC是一种罕见的侵袭性肿瘤，预后差、局部复发率高、有转移倾向，且起病隐匿，手术联合放化疗的综合治疗仍是最佳的治疗方式。.

Keywords: neuroendocrine carcinoma; nose neoplasms; prognosis.

MeSH terms

  • Carcinoma, Neuroendocrine* / pathology
  • Carcinoma, Neuroendocrine* / therapy
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Paranasal Sinus Neoplasms* / pathology
  • Paranasal Sinus Neoplasms* / therapy
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Grants and funding

河南省科技攻关计划(No：LHGJ20190186)